A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT02677896 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1150

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Hormone Sensitive Prostate Cancer

Interventions

DRUG: Enzalutamide
DRUG: Placebo

Sponsor

Astellas Pharma Global Development, Inc.

Collaborators

[object Object]